Mesoblast Limited (ASX:MSB)
1.575
-0.015 (-0.94%)
Jul 9, 2025, 4:10 PM AEST
Mesoblast Revenue
Mesoblast had revenue of $3.16M USD in the half year ending December 31, 2024, a decrease of -7.77%. This brings the company's revenue in the last twelve months to $5.67M, down -24.07% year-over-year. In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%.
Revenue (ttm)
$5.67M
Revenue Growth
-24.07%
P/S Ratio
219.56
Revenue / Employee
$77.67K
Employees
73
Market Cap
2.01B AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Ramsay Health Care | 17.12B |
Telix Pharmaceuticals | 783.21M |
Ansell | 3.00B |
Regis Healthcare | 1.10B |
Mesoblast News
- 2 days ago - Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade) - Seeking Alpha
- 8 days ago - Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday - Benzinga
- 8 days ago - Mesoblast, FDA agree on marketing application for cell therapy - Seeking Alpha
- 8 days ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 8 days ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga
- 9 days ago - Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure - GlobeNewsWire
- 27 days ago - Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD - GlobeNewsWire
- 7 weeks ago - FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil® - GlobeNewsWire